Trends in Use of Medications for Smoking Cessation in Medicare, 2007–2012

American Journal of Preventive Medicine

Volumn 51, Issue 3, 2016, Pages 301-308

  Jarlenski, Marian ^a   Hyon Baik, Seo ^b   Zhang, Yuting ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; NOSE SPRAY; VARENICLINE; DOPAMINE UPTAKE INHIBITOR; NICOTINE GUM; NICOTINIC AGENT; PRESCRIPTION DRUG;

ADMINISTRATIVE CLAIMS (HEALTH CARE); AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEPRESSION; DRUG SAFETY; DRUG USE; DRUG UTILIZATION; FEMALE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HEALTH HAZARD; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; MEDICARE; NICOTINE REPLACEMENT THERAPY; PRESCRIPTION; PROBABILITY; REIMBURSEMENT; SMOKING CESSATION; TOBACCO USE; TREND STUDY; UNSPECIFIED SIDE EFFECT; MIDDLE AGED; PROCEDURES; TRENDS; UNITED STATES; UTILIZATION;

AGED; BUPROPION; DOPAMINE UPTAKE INHIBITORS; FEMALE; HUMANS; MALE; MEDICARE; MIDDLE AGED; NICOTINIC AGONISTS; PRESCRIPTION DRUGS; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS; UNITED STATES; VARENICLINE;

EID: 84962130204     PISSN: 07493797     EISSN: 18732607     Source Type: Journal    
DOI: 10.1016/j.amepre.2016.02.018     Document Type: Article

References (25)

1. 1 The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Rockville, MD: U.S. DHHS, Public Health Service, Office of the Surgeon General; 2014.
2. 2 Xu, X., Bishop, E.E., Kennedy, S.M., Simpson, S.A., Pechacek, T.F., Annual healthcare spending attributable to cigarette smoking: an update. Am J Prev Med 48:3 (2015), 326–333, 10.1016/j.amepre.2014.10.012.
3. 3 Carter, B.D., Abnet, C.C., Feskanich, D., et al. Smoking and mortality—beyond established causes. N Engl J Med 372:7 (2015), 631–640, 10.1056/NEJMsa1407211.
4. 4 Shadel, W.G., Elliott, M.N., Haas, A.C., et al. Clinician advice to quit smoking among seniors. Prev Med 70 (2015), 83–89, 10.1016/j.ypmed.2014.11.020.
5. 5 Fiore MC, Jaén CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Clinical practice guildeline. www.surgeongeneral.gov/tobacco/treating_tobacco_use08.pdf. Published 2008. Accessed January 31, 2012.
6. 6 Cahill, K., Stevens, S., Perera, R., Lancaster, T., Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev, 5, 2013, CD009329, 10.1002/14651858.cd009329.pub2.
7. 7 Cokkinides, V.E., Ward, E., Jemal, A., Thun, M.J., Under-use of smoking-cessation treatments: results from the National Health Interview Survey, 2000. Am J Prev Med 28:1 (2005), 119–122, 10.1016/j.amepre.2004.09.007.
8. 8 Shiffman, S., Brockwell, S.E., Pillitteri, J.L., Gitchell, J.G., Use of smoking-cessation treatments in the United States. Am J Prev Med 34:2 (2008), 102–111, 10.1016/j.amepre.2007.09.033.
9. 9 McAfee, T., Babb, S., McNabb, S., Fiore, M.C., Helping smokers quit—opportunities created by the Affordable Care Act. N Engl J Med 372:1 (2015), 5–7, 10.1056/NEJMp1411437.
10. 10 Gibbons, R.D., Mann, J.J., Varenicline, smoking cessation, and neuropsychiatric adverse events. Am J Psychiatry 170:12 (2013), 1460–1467, 10.1176/appi.ajp.2013.12121599.
11. 11 Moore, T.J., Furberg, C.D., Glenmullen, J., Maltsberger, J.T., Singh, S., Suicidal behavior and depression in smoking cessation treatments. PLoS One, 6(11), 2011, e27016, 10.1371/journal.pone.0027016.
12. 12 Thomas, K.H., Martin, R.M., Knipe, D.W., Higgins, J.P., Gunnell, D., Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis. BMJ, 350, 2015, h1109.
13. 13 Centers for Medicare and Medicaid Services. Condition categories: updated chronic conditions. www.ccwdata.org/web/guest/user-documentation. Published 2014. Accessed January 16, 2015.
14. 14 Agaku, I.T., King, B.A., Husten, C.G., et al. Tobacco product use among adults—United States, 2012-2013. MMWR Morb Mortal Wkly Rep 63:25 (2014), 542–547.
15. 15 Muller, C.J., MacLehose, R.F., Estimating predicted probabilities from logistic regression: different methods correspond to different target populations. Int J Epidemiol 43:3 (2014), 962–970.
16. 16 Li, C., Dresler, C.M., Medicaid coverage and utilization of covered tobacco-cessation treatments: the Arkansas experience. Am J Prev Med 42:6 (2012), 588–595, 10.1016/j.amepre.2012.02.018.
17. 17 Graham, D.J., By, K., McKean, S., et al. Cardiovascular and mortality risks in older Medicare patients treated with varenicline or bupropion for smoking cessation: an observational cohort study. Pharmacoepidemiol Drug Saf 23:11 (2014), 1205–1212, 10.1002/pds.3678.
18. 18 National Physicians Alliance. Citizen petition to improve the safety information for Chantix. http://npalliance.org/wp-content/uploads/NPA-petition-chantix.pdf. Published 2014. Accessed June 2, 2015.
19. 19 Pfizer. Risk of SErious Neuropsychiatric adverse events with Chantix (varenicline tartrate). www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM418706.pdf. Published 2014. Accessed October 29, 2015.
20. 20 Shiffman, S., Ferguson, S.G., Rohay, J., Gitchell, J.G., Perceived safety and efficacy of nicotine replacement therapies among US smokers and ex-smokers: relationship with use and compliance. Addiction 103:8 (2008), 1371–1378, 10.1111/j.1360-0443.2008.02268.x.
21. 21 Rigotti, N.A., Munafo, M.R., Stead, L.F., Smoking cessation interventions for hospitalized smokers: a systematic review. Arch Intern Med 168:18 (2008), 1950–1960, 10.1001/archinte.168.18.1950.
22. 22 CDC. Quitting smoking among adults—United States, 2001-2010. MMWR Morb Mortal Wkly Rep 60:44 (2011), 1513–1519.
23. 23 Balmford, J., Borland, R., Hammond, D., Cummings, K.M., Adherence to and reasons for premature discontinuation from stop-smoking medications: data from the ITC Four-Country Survey. Nicotine Tob Res 13:2 (2011), 94–102, 10.1093/ntr/ntq215.
24. 24 Park, E.R., Gareen, I.F., Japuntich, S., et al. Primary care provider-delivered smoking cessation interventions and smoking cessation among participants in the National Lung Screening Trial. JAMA Intern Med 175:9 (2015), 1509–1516, 10.1001/jamainternmed.2015.2391.
25. 25 Joyce, G.F., Niaura, R., Maglione, M., et al. The effectiveness of covering smoking cessation services for medicare beneficiaries. Health Serv Res 43:6 (2008), 2106–2123, 10.1111/j.1475-6773.2008.00891.x.